ALLAKOS
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.
ALLAKOS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2012-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.allakos.com
Total Employee:
101+
Status:
Active
Contact:
650-597-5002
Total Funding:
312.45 M USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 Google Google Maps API CloudFront Invalid Certificate Dates Mobile Optimized New Relic QUIC
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Pleno
Pleno is a biotechnology company that aims speeding up disease diagnosis and treatment.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Board_member
2012-01-01
Board_member
2023-08-01
Board_member
Board_member
2017-12-01
Board_member
Board_member
Board_member
2018-06-01
Board_member
Current Employees Featured
Baird Radford Chief Financial Officer @ Allakos
Chief Financial Officer
2021-04-01
Sally Bolmer VP, Regulatory Affairs and Drug Development @ Allakos
VP, Regulatory Affairs and Drug Development
Ruby Casareno Senior Vice President, Technical Operations @ Allakos
Senior Vice President, Technical Operations
2017-01-01
Mark Asbury Chief Legal Officer, General Counsel @ Allakos
Chief Legal Officer, General Counsel
2018-01-01
Adam Tomasi President , Chief Operating Officer & Chief Financial Officer @ Allakos
President , Chief Operating Officer & Chief Financial Officer
2019-01-01
Robert Alexander Chief Executive Officer @ Allakos
Chief Executive Officer
2017-04-01
Henrik Sandvad Rasmussen Chief Medical Officer @ Allakos
Chief Medical Officer
2017-01-01
Founder
Stock Details
Investors List
Alta Partners
Alta Partners investment in Post-IPO Equity - Allakos
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Allakos
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Allakos
Frazier Life Sciences
Frazier Life Sciences investment in Post-IPO Equity - Allakos
TCG Crossover
TCG Crossover investment in Post-IPO Equity - Allakos
Logos Capital
Logos Capital investment in Post-IPO Equity - Allakos
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Allakos
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Allakos
RTW Investments
RTW Investments investment in Post-IPO Equity - Allakos
Braidwell
Braidwell investment in Post-IPO Equity - Allakos
Official Site Inspections
http://www.allakos.com Semrush global rank: 4.84 M Semrush visits lastest month: 1.8 K
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "Allakos"
Management team for Allakos
Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor …See details»
Allakos │ Therapeutic antibodies │ Mast cells and Eosinophils
Allakos is a clinical stage biotechnology company that has been developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, …See details»
Allakos - Crunchbase Company Profile & Funding
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, …See details»
Allakos - Funding, Financials, Valuation & Investors - Crunchbase
Allakos is registered under the ticker NASDAQ:ALLK . Their stock opened with $18.00 in its Jul 23, 2018 IPO. Stock Symbol NASDAQ:ALLK ; Valuation at IPO $728M; Money Raised at IPO …See details»
Allakos Inc Company Profile - Allakos Inc Overview - GlobalData
Allakos Inc (Allakos) is a clinical-stage biotechnology company that develops antibodies that target immunomodulatory receptors present on immune effector cells. The company …See details»
Allakos - Contacts, Employees, Board Members, Advisors & Alumni
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases. ... Experience the new Crunchbase, powered by AI . …See details»
Allakos Company Profile - Office Locations, Competitors ... - Craft
Allakos is a biotechnology company that develops therapeutics targeting allergic, inflammatory, and proliferative diseases. It creates monoclonal antibodies that activate or block inhibitory …See details»
Allakos, Inc. - Drug pipelines, Patents, Clinical trials
Mar 8, 2025 Allakos is a biopharmaceutical company that specializes in creating antibody-based therapies to combat diseases caused by the overactivity of the T-helper type 2 immune response. ... The statistics for drugs in the Pipeline is …See details»
Allakos - Overview, News & Similar companies | ZoomInfo.com
Who is Allakos. Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, …See details»
Allakos Inc. Enters into Agreement to Be Acquired by Concentra ...
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Allakos’ …See details»
Bay Area biotech firm Allakos suddenly on brink of collapse after …
Jan 27, 2025 Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical stage drug failed a trial. SF Gate Logo Hearst …See details»
Allakos Inc. (ALLK) Company Profile & Overview - StockAnalysis
Jul 19, 2018 Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, …See details»
Board of Directors - Allakos
During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and …See details»
Allakos Inc. Enters into Agreement to Be Acquired by Concentra ...
10 hours ago Allakos is a biotechnology company that has been developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, …See details»
Allakos stock surges on reverse merger deal (ALLK:NASDAQ)
9 hours ago Allakos (NASDAQ:ALLK) stock surges as the company announces a merger with Concentra Biosciences for $0.33/share in cash. Read more here.See details»
Allakos Inc. (ALLK): history, ownership, mission, how it works
[relinking] Home History Owners Mission How It Works How It Makes Money Allakos Inc. (ALLK) Information A Brief History of Allakos Inc. Company Overview Allakos Inc. is a clinical-stage …See details»
Allakos - Work in biotech
Allakos is developing antibody-based therapeutics to treat allergic and inflammatory diseases. Eosinophils and mast cells, both types of immune cells, play a role in pathogenesis of many …See details»
Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share
9 hours ago Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune …See details»
Allakos to Be Acquired for 33 Cents a Share - MarketWatch
22 hours ago Allakos on Wednesday said Concentra Biosciences, controlled by life sciences-focused investment firm Tang Capital, has agreed to pay 33 cents a share in cash for the …See details»
Allakos Provides Business Update and Reports Fourth Quarter and …
Mar 14, 2024 Upcoming Allakos Anticipated Milestones. Report safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of IV AK006 in healthy volunteers, …See details»